Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease

British Medical Bulletin

Volumn 102, Issue 1, 2012, Pages 89-113

  Fledrich, Robert ^a   Stassart, Ruth M ^a,b   Sereda, Michael W ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

animal model; Charcot Marie Tooth; demyelination; experimental therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTIGESTAGEN; ASCORBIC ACID; BIOLOGICAL MARKER; CCAAT ENHANCER BINDING PROTEIN; COLONY STIMULATING FACTOR 1; CURCUMIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN PROTEIN; MYOTUBULARIN RELATED PROTEIN 13; MYOTUBULARIN RELATED PROTEIN 2; NEUROTROPHIN 3; ONAPRISTONE; PHOSPHATASE; PLACEBO; PURINERGIC P2X7 RECEPTOR; RAPAMYCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EARLY GROWTH RESPONSE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CALORIC RESTRICTION; DEMYELINATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL THERAPY; GENE MUTATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NERVE REGENERATION; NONHUMAN; PERIPHERAL NERVE; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; RAT; REMYELINIZATION; REVIEW; SCORING SYSTEM; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; MICE; MOLECULAR TARGETED THERAPY; RATS;

EID: 84861812079     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/lds010     Document Type: Review

References (167)

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98-118.
2. Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991;1:19-29.
3. Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16:1-14.
4. Schenone A, Nobbio L, Monti Bragadin M et al. Inherited neuropathies. Curr Treat Options Neurol 2011;13:160-79.
5. Siskind CE, Shy ME. Genetics of neuropathies. Semin Neurol 2011;31:494-505.
6. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009;8:654-67.
7. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968;18:603-18.
8. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103:259-80. (Pubitemid 10046623)
9. Shy ME, Lewis JR, Chance PF et al. Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features. In: Dyck PJ, Thomas PK (eds). Peripheral Neuropathy, Vol. 2: 4th edn. Philadelphia: Saunders, 2005,1623-58.
10. Martini R, Zielasek J, Toyka KV et al. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet 1995;11:281-6.
11. Huxley C, Passage E, Manson A et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 1996;5:563-9. (Pubitemid 26141268)
12. Sereda M, Griffiths I, Puhlhofer A et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996;16:1049-60. (Pubitemid 26171699)
13. Magyar JP, Martini R, Ruelicke T et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 1996;16:5351-60. (Pubitemid 26277864)
14. Suter U, Welcher AA, Ozcelik T et al. Trembler mouse carries a point mutation in a myelin gene. Nature 1992;356:241-4.
15. Wrabetz L, Feltri ML, Suter U. Myelin Biology and Disorders, Vol. 2. Amsterdam: Elsevier Academy, 2004.
16. Timmerman V, Lupski JR, De Jonghe P. Molecular genetics, biology, and therapy for inherited peripheral neuropathies. Neuromolecular Med 2006;8:1-2.
17. Meyer zu Horste G, Nave KA. Animal models of inherited neuropathies. Curr Opin Neurol 2006;19:464-73. (Pubitemid 44395268)
18. Sereda MW, Nave KA. Animal models of Charcot-Marie-Tooth disease type 1A. Neuromolecular Med 2006;8:205-16.
19. Nave KA, Sereda MW, Ehrenreich H. Mechanisms of disease: inherited demyelinating neuropathies-from basic to clinical research. Nat Clin Pract Neurol 2007;3:453-64. (Pubitemid 47202502)
20. Burns J, Ouvrier RA, Yiu EM et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009;8:537-44.
21. Micallef J, Attarian S, Dubourg O et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebocontrolled trial. Lancet Neurol 2009;8:1103-10.
22. Verhamme C, de Haan RJ, Vermeulen M et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009;7:70.
23. Pareyson D, Reilly MM, Schenone A et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320-8.
24. Lupski JR, de Oca-Luna RM, Slaugenhaupt S et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-32. (Pubitemid 121001361)
25. Raeymaekers P, Timmerman V, Nelis E et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991;1:93-7.
26. Palau F, Lofgren A, De Jonghe P et al. Origin of the de novo duplication in Charcot-Marie-Tooth disease type 1A: unequal nonsister chromatid exchange during spermatogenesis. Hum Mol Genet 1993;2:2031-5. (Pubitemid 24003394)
27. Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci 2003;4:714-26. (Pubitemid 37280151)
28. Snipes GJ, Suter U, Welcher AA et al. Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 1992;117:225-38.
29. Yoshikawa H, Nishimura T, Nakatsuji Y et al. Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A. Ann Neurol 1994;35:445-50. (Pubitemid 24107852)
30. Hanemann CO, Stoll G, D'Urso D et al. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies. J Neurosci Res 1994;37:654-9. (Pubitemid 24119379)
31. Huxley C, Passage E, Robertson AM et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 1998;7:449-58. (Pubitemid 28120635)
32. Robertson AM, Perea J, McGuigan A et al. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat 2002;200:377-90. (Pubitemid 34498532)
33. Sereda MW, Meyer zu Horste G, Suter U et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533-7. (Pubitemid 38004782)
34. Grandis M, Leandri M, Vigo T et al. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Exp Neurol 2004;190:213-23. (Pubitemid 39335720)
35. Fledrich R, Schlotter-Weigel B, Schnizer TJ et al. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain 2012;135:72-87.
36. Meyer zu Horste G, Prukop T, Liebetanz D et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007;61:61-72. (Pubitemid 46214245)
37. Kaku DA, Parry GJ, Malamut R et al. Nerve conduction studies in Charcot-Marie-Tooth polyneuropathy associated with a segmental duplication of chromosome 17. Neurology 1993;43:1806-8. (Pubitemid 23307959)
38. Garcia CA, Malamut RE, England JD et al. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology 1995;45:2090-3.
39. Niemann S, Sereda MW, Suter U et al. Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J Neurosci 2000;20:4120-8. (Pubitemid 30365682)
40. Passage E, Norreel JC, Noack-Fraissignes P et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401. (Pubitemid 38508518)
41. Verhamme C, King RH, ten Asbroek AL et al. Myelin and axon pathology in a long-term study of PMP22-overexpressing mice. J Neuropathol Exp Neurol 2011;70:386-98.
42. Chance PF, Alderson MK, Leppig KA et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993;72:143-51. (Pubitemid 23029701)
43. Kumar N, Muley S, Pakiam A et al. Phenotypic variability leads to under-recognition of HNPP. J Clin Neuromuscul Dis 2002;3:106-12. (Pubitemid 34256823)
44. Lupski JR, Chance PF. Hereditary motor and sensory neuropathies involving altered dosage of mutation of PMP22: the CMT1A duplication and HNPP deletion. In: Dyck PJ, Thomas PK (eds). Peripheral Neuropathy, Vol. 2, 4th edn. Philadelphia: Saunders, 2005,1659-80.
45. Adlkofer K, Martini R, Aguzzi A et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 1995;11:274-80.
46. Adlkofer K, Frei R, Neuberg DH et al. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci 1997;17:4662-71. (Pubitemid 27246924)
47. Bai Y, Zhang X, Katona I et al. Conduction block in PMP22 deficiency. J Neurosci 2010;30:600-8.
48. Szigeti K, Nelis E, Lupski JR. Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies. Neuromolecular Med 2006;8:243-54.
49. Gess B, Jeibmann A, Schirmacher A et al. Report of a novel mutation in the PMP22 gene causing an axonal neuropathy. Muscle Nerve 2011;43:605-9.
50. Robertson AMHC. Transgenic models of inherited neuropathy. In: Dyck PJ, Thomas PK (eds). Peripheral Neuropathy, Vol. 2, 4th edn. Amsterdam: Elsevier Saunders, 2005,1561-83.
51. Suter U, Moskow JJ, Welcher AA et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA 1992;89:4382-6.
52. Valentijn LJ, Baas F, Wolterman RA et al. Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat Genet 1992;2:288-91.
53. Henry EW, Cowen JS, Sidman RL. Comparison of Trembler and Trembler-J mouse phenotypes: varying severity of peripheral hypomyelination. J Neuropathol Exp Neurol 1983;42:688-706. (Pubitemid 14204800)
54. Henry EW, Sidman RL. Long lives for homozygous trembler mutant mice despite virtual absence of peripheral nerve myelin. Science 1988;241:344-6.
55. Notterpek L, Ryan MC, Tobler AR et al. PMP22 accumulation in aggresomes: implications for CMT1A pathology. Neurobiol Dis 1999;6:450-60. (Pubitemid 29496222)
56. Naef R, Suter U. Impaired intracellular trafficking is a common disease mechanism of PMP22 point mutations in peripheral neuropathies. Neurobiol Dis 1999;6:1-14. (Pubitemid 29156464)
57. Colby J, Nicholson R, Dickson KM et al. PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells. Neurobiol Dis 2000;7:561-73. (Pubitemid 32044282)
58. Tobler AR, Liu N, Mueller L et al. Differential aggregation of the trembler and trembler J mutants of peripheral myelin protein 22. Proc Natl Acad Sci USA 2002;99:483-8. (Pubitemid 34060387)
59. Fortun J, Go JC, Li J et al. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol Dis 2006;22:153-64.
60. Greenfield S, Brostoff S, Eylar EH et al. Protein composition of myelin of the peripheral nervous system. J Neurochem 1973;20:1207-16.
61. Filbin MT, Tennekoon GI. Homophilic adhesion of the myelin P0 protein requires glycosylation of both molecules in the homophilic pair. J Cell Biol 1993;122:451-9. (Pubitemid 23210471)
62. Shy ME. Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci 2006;242:55-66.
63. Warner LE, Hilz MJ, Appel SH et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996;17:451-60. (Pubitemid 26322216)
64. De Jonghe P, Timmerman V, Ceuterick C et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999;122(Pt 2):281-90. (Pubitemid 29067210)
65. Misu K, Yoshihara T, Shikama Y et al. An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val). J Neurol Neurosurg Psychiatry 2000;69:806-11.
66. Auer-Grumbach M, Strasser-Fuchs S, Robl T et al. Late onset Charcot-Marie-Tooth 2 syndrome caused by two novel mutations in the MPZ gene. Neurology 2003;61:1435-7. (Pubitemid 37463388)
67. Li J, Bai Y, Ianakova E et al. Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. J Comp Neurol 2006;498:252-65. (Pubitemid 44182464)
68. Marttila M, Rautenstrauss B, Huehne K et al. A novel mutation of myelin protein zero associated with late-onset predominantly axonal Charcot-Marie-Tooth disease. J Neurol 2012 [Epub ahead of print].
69. Hoyer H, Braathen GJ, Eek AK et al. Charcot-Marie-Tooth caused by a copy number variation in myelin protein zero. Eur J Med Genet 2011;54:e580-3.
70. Maeda MH, Mitsui J, Soong BW et al. Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol 2012;71:84-92.
71. Wrabetz L, Feltri ML, Quattrini A et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 2000;148:1021-34.
72. Inoue K, Khajavi M, Ohyama T et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 2004;36:361-9. (Pubitemid 38437258)
73. Khajavi M, Inoue K, Wiszniewski W et al. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet 2005;77:841-50. (Pubitemid 41513284)
74. Hayasaka K, Himoro M, Sato W et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993;5:31-4. (Pubitemid 23261514)
75. Kulkens T, Bolhuis PA, Wolterman RA et al. Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet 1993;5:35-9. (Pubitemid 23261515)
76. Wrabetz L, D'Antonio M, Pennuto M et al. Different intracellular pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice. J Neurosci 2006;26:2358-68. (Pubitemid 44699045)
77. Abrams CK, Scherer SS. Gap junctions in inherited human disorders of the central nervous system. Biochim Biophys Acta 2011 [Epub ahead of print].
78. Kleopa KA, Scherer SS. Molecular genetics of X-linked Charcot-Marie-Tooth disease. Neuromolecular Med 2006;8:107-22.
79. Hahn AF, Ainsworth PJ, Naus CC et al. Clinical and pathological observations in men lacking the gap junction protein connexin 32. Muscle Nerve Suppl 2000;9:S39-48.
80. Dubourg O, Tardieu S, Birouk N et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain 2001;124:1958-67. (Pubitemid 32945897)
81. Young P, Suter U. Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res Brain Res Rev 2001;36:213-21. (Pubitemid 33020751)
82. Nelles E, Butzler C, Jung D et al. Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci USA 1996;93:9565-70. (Pubitemid 26296648)
83. Anzini P, Neuberg DH, Schachner M et al. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci 1997;17:4545-51. (Pubitemid 27246912)
84. Scherer SS, Xu YT, Nelles E et al. Connexin32-null mice develop demyelinating peripheral neuropathy. Glia 1998;24:8-20. (Pubitemid 28370208)
85. Jeng LJ, Balice-Gordon RJ, Messing A et al. The effects of a dominant connexin32 mutant in myelinating Schwann cells. Mol Cell Neurosci 2006;32:283-98. (Pubitemid 44026520)
86. Scherer SS, Xu YT, Messing A et al. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice. J Neurosci 2005;25:1550-9. (Pubitemid 40250731)
87. Kobsar I, Berghoff M, Samsam M et al. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 2003;126:804-13. (Pubitemid 36372981)
88. Groh J, Heinl K, Kohl B et al. Attenuation of MCP-1/CCL2 expression ameliorates neuropathy in a mouse model for Charcot-Marie-Tooth 1X. Hum Mol Genet 2010;19:3530-43.
89. Sherman DL, Fabrizi C, Gillespie CS et al. Specific disruption of a schwann cell dystrophinrelated protein complex in a demyelinating neuropathy. Neuron 2001;30:677-87. (Pubitemid 32607333)
90. Court FA, Sherman DL, Pratt T et al. Restricted growth of Schwann cells lacking Cajal bands slows conduction in myelinated nerves. Nature 2004;431:191-5. (Pubitemid 39243472)
91. Guilbot A, Williams A, Ravise N et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 2001;10:415-21. (Pubitemid 32166552)
92. Gillespie CS, Sherman DL, Fleetwood-Walker SM et al. Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron 2000;26:523-31.
93. Topilko P, Schneider-Maunoury S, Levi G et al. Krox-20 controls myelination in the peripheral nervous system. Nature 1994;371:796-9. (Pubitemid 24333867)
94. Warner LE, Mancias P, Butler IJ et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18:382-4. (Pubitemid 28158170)
95. Vandenberghe N, Upadhyaya M, Gatignol A et al. Frequency of mutations in the early growth response 2 gene associated with peripheral demyelinating neuropathies. J Med Genet 2002;39:e81.
96. Bolino A, Muglia M, Conforti FL et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000;25:17-9. (Pubitemid 30257029)
97. Houlden H, King RH, Wood NW et al. Mutations in the 50 region of the myotubularinrelated protein 2 (MTMR2) gene in autosomal recessive hereditary neuropathy with focally folded myelin. Brain 2001;124:907-15. (Pubitemid 32458503)
98. Suter U. Phosphoinositides and Charcot-Marie-tooth disease: new keys to old questions. Cell Mol Life Sci 2007;64:3261-5.
99. Goebbels S, Oltrogge JH, Kemper R et al. Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J Neurosci 2010;30:8953-64.
100. Bolino A, Bolis A, Previtali SC et al. Disruption of Mtmr2 produces CMT4B1-like europathy with myelin outfolding and impaired spermatogenesis. J Cell Biol 2004;167:711-21. (Pubitemid 39565151)
101. Bonneick S, Boentert M, Berger P et al. An animal model for Charcot-Marie-Tooth disease type 4B1. Hum Mol Genet 2005;14:3685-95. (Pubitemid 41754668)
102. Robinson FL, Niesman IR, Beiswenger KK et al. Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc Natl Acad Sci USA 2008;105:4916-21. (Pubitemid 351753846)
103. Azzedine H, Bolino A, Taieb T et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003;72:1141-53. (Pubitemid 36530002)
104. Senderek J, Bergmann C, Weber S et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 2003;12:349-56. (Pubitemid 36204431)
105. Chow CY, Zhang Y, Dowling JJ et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007;448:68-72. (Pubitemid 47036999)
106. Nicholson G, Lenk GM, Reddel SW et al. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P phosphatase FIG4. Brain 2011;134:1959-71.
107. Vaccari I, Dina G, Tronchere H et al. Genetic interaction between MTMR2 and FIG4 phospholipid phosphatases involved in Charcot-Marie-Tooth neuropathies. PLoS Genet 2012;7:e1002319.
108. Niemann S, Sereda MW, Rossner M et al. The 'CMT rat': peripheral neuropathy and dysmyelination caused by transgenic overexpression of PMP22. Ann N Y Acad Sci 1999;883:254-61. (Pubitemid 129495434)
109. Jones EA, Lopez-Anido C, Srinivasan R et al. Regulation of the PMP22 gene through an intronic enhancer. J Neurosci 2011;31:4242-50.
110. Jones EA, Brewer MH, Srinivasan R et al. Distal enhancers upstream of the Charcot-Marie-Tooth type 1A disease gene PMP22. Hum Mol Genet 2012;21:1581-91.
111. Weterman MA, van Ruissen F, de Wissel M et al. Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease. Eur J Hum Genet 2010;18:421-8.
112. Desarnaud F, Do Thi AN, Brown AM et al. Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J Neurochem 1998;71:1765-8. (Pubitemid 28443052)
113. Melcangi RC, Magnaghi V, Cavarretta I et al. Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible mechanisms of action. J Neurosci Res 1999;56:349-57. (Pubitemid 29226952)
114. Birouk N, Gouider R, Le Guern E et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 1997;120(Pt 5):813-23. (Pubitemid 27222986)
115. Podratz JL, Rodriguez EH, Windebank AJ. Antioxidants are necessary for myelination of dorsal root ganglion neurons, in vitro. Glia 2004;45:54-8. (Pubitemid 38076227)
116. Saberan-Djoneidi D, Sanguedolce V, Assouline Z et al. Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 2000;248:223-31. (Pubitemid 30259433)
117. Berciano J, Garcia A, Calleja J et al. Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with charcot-marie-tooth disease 1A duplication. Neuromuscul Disord 2000;10:419-24. (Pubitemid 30433812)
118. Meyer zu Horste G, Miesbach TA, Muller JI et al. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration. Neurobiol Dis 2011;42:1-8.
119. Meier C, Parmantier E, Brennan A et al. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci 1999;19:3847-59. (Pubitemid 29222261)
120. Sahenk Z, Nagaraja HN, McCracken BS et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65:681-9. (Pubitemid 41285845)
121. Schmid CD, Stienekemeier M, Oehen S et al. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci 2000;20:729-35. (Pubitemid 30225575)
122. Berghoff M, Samsam M, Muller M et al. Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol Cell Neurosci 2005;28:118-27. (Pubitemid 39656017)
123. Kobsar I, Hasenpusch-Theil K, Wessig C et al. Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J Neurosci Res 2005;81:857-64. (Pubitemid 41532151)
124. Fischer S, Weishaupt A, Troppmair J et al. Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway. Glia 2008;56:836-43.
125. Martini R, Fischer S, Lopez-Vales R et al. Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. Glia 2008;56:1566-77.
126. Kohl B, Groh J, Wessig C et al. Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A. Neurobiol Dis 2010;38:78-84.
127. Groh J, Weis J, Zieger H et al. Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for Charcot-Marie-Tooth disease type 1X. Brain 2012;135:88-104.
128. Kohl B, Fischer S, Groh J et al. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy. Am J Pathol 2010;176:1390-9.
129. Wessig C, Jestaedt L, Sereda MW et al. Gadofluorine M-enhanced magnetic resonance nerve imaging: comparison between acute inflammatory and chronic degenerative demyelination in rats. Exp Neurol 2008;210:137-43. (Pubitemid 351258076)
130. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40. (Pubitemid 32225829)
131. Smith KJ, Hall SM, Schauf CL. Vesicular demyelination induced by raised intracellular calcium. J Neurol Sci 1985;71:19-37. (Pubitemid 16223279)
132. Stevens B, Fields RD. Response of Schwann cells to action potentials in development. Science 2000;287:2267-71. (Pubitemid 30177032)
133. Wilson HL, Wilson SA, Surprenant A et al. Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. J Biol Chem 2002;277:34017-23.
134. Nobbio L, Sturla L, Fiorese F et al. P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy. J Biol Chem 2009;284:23146-58.
135. Pareek S, Notterpek L, Snipes GJ et al. Neurons promote the translocation of peripheral myelin protein 22 into myelin. J Neurosci 1997;17:7754-62. (Pubitemid 27426214)
136. Sanders CR, Ismail-Beigi F, McEnery MW. Mutations of peripheral myelin protein 22 result in defective trafficking through mechanisms which may be common to diseases involving tetraspan membrane proteins. Biochemistry 2001;40:9453-9. (Pubitemid 32757883)
137. Ryan MC, Shooter EM, Notterpek L. Aggresome formation in neuropathy models based on peripheral myelin protein 22 mutations. Neurobiol Dis 2002;10:109-18. (Pubitemid 34775464)
138. Fortun J, Dunn WA Jr, Joy S et al. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci 2003;23:10672-80. (Pubitemid 37485281)
139. Fortun J, Verrier JD, Go JC et al. The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones. Neurobiol Dis 2007;25:252-65. (Pubitemid 46124007)
140. Rangaraju S, Verrier JD, Madorsky I et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci 2010;30:11388-97.
141. Madorsky I, Opalach K, Waber A et al. Intermittent fasting alleviates the neuropathic phenotype in a mouse model of Charcot-Marie-Tooth disease. Neurobiol Dis 2009;34:146-54.
142. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005;6:11-22. (Pubitemid 40052135)
143. Rangaraju S, Madorsky I, Pileggi JG et al. Pharmacological induction of the heat shock response improves myelination in a neuropathic model. Neurobiol Dis 2008;32:105-15.
144. Khajavi M, Shiga K, Wiszniewski W et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007;81:438-53. (Pubitemid 47330204)
145. Egan ME, Pearson M, Weiner SA et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600-2. (Pubitemid 38541921)
146. Teijido O, Martinez A, Pusch M et al. Localization and functional analyses of the MLC1 protein involved in megalencephalic leukoencephalopathy with subcortical cysts. Hum Mol Genet 2004;13:2581-94. (Pubitemid 39485407)
147. Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901. (Pubitemid 40280072)
148. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007;595:197-212.
149. Pennuto M, Tinelli E, Malaguti M et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 2008;57:393-405. (Pubitemid 351179164)
150. Zinszner H, Kuroda M, Wang X et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998;12:982-95. (Pubitemid 28204605)
151. Rutkowski DT, Arnold SM, Miller CN et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 2006;4:e374.
152. D'Antonio M, Feltri ML, Wrabetz L. Myelin under stress. J Neurosci Res 2009;87:3241-9.
153. Ajroud-Driss S, Deng HX, Siddique T. Recent advances in the genetics of hereditary axonal sensory-motor neuropathies type 2. Curr Neurol Neurosci Rep 2011;11:262-73.
154. Zhao C, Takita J, Tanaka Y et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001;105:587-97. (Pubitemid 32524112)
155. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994;13:975-88. (Pubitemid 24347310)
156. De Sandre-Giovannoli A, Chaouch M, Kozlov S et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002;70:726-36. (Pubitemid 34177926)
157. d'Ydewalle C, Krishnan J, Chiheb DM et al. HDAC6 inhibitors reverse
158. Dequen F, Filali M, Lariviere RC et al. Reversal of neuropathy phenotypes in conditional mouse model of Charcot-Marie-Tooth disease type 2E. Hum Mol Genet 2010;19:2616-29.
159. Shy ME, Blake J, Krajewski K et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209-14.
160. Reilly MM, Shy ME, Muntoni F et al. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010;20:839-46.
161. de Visser M, Verhamme C. Ascorbic acid for treatment in CMT1A: what's next?. Lancet Neurol 2011;10:291-3.
162. Giese KP, Martini R, Lemke G et al. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 1992;71:565-76.
163. Runker AE, Kobsar I, Fink T et al. Pathology of a mouse mutation in peripheral myelin protein P0 is characteristic of a severe and early onset form of human Charcot-Marie-Tooth type 1B disorder. J Cell Biol 2004;165:565-73. (Pubitemid 38679621)
164. Schneider-Maunoury S, Topilko P, Seitandou T et al. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell 1993;75:1199-214. (Pubitemid 24006116)
165. Nagarajan R, Svaren J, Le N et al. EGR2 mutations in inherited neuropathies dominantnegatively inhibit myelin gene expression. Neuron 2001;30:355-68. (Pubitemid 32530581)
166. Suh JG, Ichihara N, Saigoh K et al. An in-frame deletion in peripheral myelin protein-22 gene causes hypomyelination and cell death of the Schwann cells in the new Trembler mutant mice. Neuroscience 1997;79:735-44. (Pubitemid 27292670)
167. Isaacs AM, Davies KE, Hunter AJ et al. Identification of two new Pmp22 mouse mutants using large-scale mutagenesis and a novel rapid mapping strategy. Hum Mol Genet 2000;9:1865-71. (Pubitemid 30608619)